Abstract |
Similar risk reduction but fewer side effects would predict more uptake and compliance with low (5 mg) versus full (20 mg) dose tamoxifen. Benefit with low dose is demonstrated for perimenopausal/postmenopausal women with intraepithelial neoplasia and high lesion Ki-67. Longer follow-up needed to determine benefit with low lesion Ki-67.See related article by DeCensi et al., p. 3576.
|
Authors | Carol J Fabian |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 27
Issue 13
Pg. 3510-3511
(07 01 2021)
ISSN: 1557-3265 [Electronic] United States |
PMID | 33926916
(Publication Type: Journal Article, Comment)
|
Copyright | ©2021 American Association for Cancer Research. |
Chemical References |
|
Topics |
- Breast
- Breast Diseases
- Carcinoma in Situ
- Female
- Humans
- Precancerous Conditions
(drug therapy)
- Tamoxifen
(therapeutic use)
|